[HTML][HTML] An open-label, single-arm, phase I/II study of lower-dose decitabine based therapy in patients with advanced hepatocellular carcinoma
Q Mei, M Chen, X Lu, X Li, F Duan, M Wang, G Luo… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Q Mei, M Chen, X Lu, X Li, F Duan, M Wang, G Luo, W Han
Oncotarget, 2015•ncbi.nlm.nih.govAn open-label, single-arm, phase I/II study of lower-dose decitabine based therapy in patients
with advanced hepatocellular carcinoma - PMC Back to Top Skip to main content NIH NLM
Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search
PMC Full-Text Archive Search in PMC Advanced Search User Guide Journal List Oncotarget
v.6(18); 2015 Jun 30 PMC4599300 Other Formats PDF (3.5M) Actions Cite Collections Share
Permalink Copy RESOURCES Similar articles Cited by other articles Links to NCBI Databases …
with advanced hepatocellular carcinoma - PMC Back to Top Skip to main content NIH NLM
Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search
PMC Full-Text Archive Search in PMC Advanced Search User Guide Journal List Oncotarget
v.6(18); 2015 Jun 30 PMC4599300 Other Formats PDF (3.5M) Actions Cite Collections Share
Permalink Copy RESOURCES Similar articles Cited by other articles Links to NCBI Databases …
Abstract
Purpose
We conducted this phase I/II clinical trial to determine the safety and efficacy of lower-dose decitabine based therapy in pretreated patients with advanced HCC.
ncbi.nlm.nih.gov